Bordetella pertussis: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Addition of missing information, addition of new citations.
Line 18: Line 18:
'''''Bordetella pertussis''''' is a [[Gram-negative]], [[Aerobic organism|aerobic]], [[pathogenic bacteria|pathogenic]], [[Bacterial capsule|encapsulated]] [[coccobacillus]] of the genus ''[[Bordetella]]'', and the causative agent of [[pertussis]] or whooping cough. Unlike ''[[Bordetella bronchiseptica|B. bronchiseptica]]'', ''B. pertussis'' is not [[motile]]. Its virulence factors include [[pertussis toxin]], [[Filamentous haemagglutinin adhesin|filamentous hæmagglutinin]], [[pertactin]], [[Fimbria (bacteriology)|fimbria]], and [[tracheal cytotoxin]].
'''''Bordetella pertussis''''' is a [[Gram-negative]], [[Aerobic organism|aerobic]], [[pathogenic bacteria|pathogenic]], [[Bacterial capsule|encapsulated]] [[coccobacillus]] of the genus ''[[Bordetella]]'', and the causative agent of [[pertussis]] or whooping cough. Unlike ''[[Bordetella bronchiseptica|B. bronchiseptica]]'', ''B. pertussis'' is not [[motile]]. Its virulence factors include [[pertussis toxin]], [[Filamentous haemagglutinin adhesin|filamentous hæmagglutinin]], [[pertactin]], [[Fimbria (bacteriology)|fimbria]], and [[tracheal cytotoxin]].


The bacterium is spread by airborne droplets; its incubation period is 9–10 days on average (range 6–20 days).<ref>Heymann, David L. (ed): Pertussis; in Control of Communicable Diseases Manual. p. 457. American Public Health Association, Washington DC, 2008, {{ISBN|978-0-87553-189-2}}</ref> Humans are the only known reservoir for ''B. pertussis''.<ref>{{harvnb|Pink Book|2015|loc=[https://www.cdc.gov/vaccines/pubs/pinkbook/pert.html Ch. 16: Pertussis]}}</ref> The complete ''B. pertussis'' [[genome]] of 4,086,186 base pairs was published in 2003.<ref>{{cite journal |vauthors=Parkhill J |display-authors=etal | year = 2003 | title = Comparative analysis of the genome sequences of ''Bordetella pertussis'', ''Bordetella parapertussis'' and ''Bordetella bronchiseptica'' | url = | journal = Nature Genetics | volume = 35 | issue = 1| pages = 32–40 | doi=10.1038/ng1227 | pmid=12910271}}</ref>
The bacterium is spread by airborne droplets; its incubation period is 7–10 days on average (range 6–20 days).<ref>Heymann, David L. (ed): Pertussis; in Control of Communicable Diseases Manual. p. 457. American Public Health Association, Washington DC, 2008, {{ISBN|978-0-87553-189-2}}</ref><ref name=":0">{{Cite book|url=http://worldcat.org/oclc/301147153|title=Relevé épidémiologique hebdomadaire (Online) = Weekly epidemiological record.|last=Organization.|first=Organisation mondiale de la santé. World Health|date=1998-|publisher=Organisation mondiale de la sante|oclc=301147153}}</ref> Humans are the only known reservoir for ''B. pertussis''.<ref>{{harvnb|Pink Book|2015|loc=[https://www.cdc.gov/vaccines/pubs/pinkbook/pert.html Ch. 16: Pertussis]}}</ref> The complete ''B. pertussis'' [[genome]] of 4,086,186 base pairs was published in 2003.<ref>{{cite journal |vauthors=Parkhill J |display-authors=etal | year = 2003 | title = Comparative analysis of the genome sequences of ''Bordetella pertussis'', ''Bordetella parapertussis'' and ''Bordetella bronchiseptica'' | url = | journal = Nature Genetics | volume = 35 | issue = 1| pages = 32–40 | doi=10.1038/ng1227 | pmid=12910271}}</ref> Compared to its closest relative ''B. bronchiseptica'', the genome size is greatly reduced. This is mainly due to the adaptation to one host species (human) and the loss of capability of survival outside of a host body.<ref name=":1">{{Cite book|url=https://www.worldcat.org/oclc/159579443|title=Bordetella : molecular microbiology|date=2007|publisher=Horizon Bioscience|others=Locht, Camille.|isbn=9781904933311|location=Wymondham|oclc=159579443}}</ref>

== History ==
The first to describe this disease was french physician [[Guillaume de Baillou]] after the epidemic of 1578. The causative agent of pertussis was identified and isolated by [[Jules Bordet]] and [[Octave Gengou]].<ref>{{Cite book|url=https://link.springer.com/referencework/10.1007%2F978-3-642-30144-5|title=The Prokaryotes|date=2013|publisher=Springer Berlin Heidelberg|isbn=9783642301438|editor-last=Rosenberg|editor-first=Eugene|location=Berlin, Heidelberg|language=en-gb|doi=10.1007/978-3-642-30144-5|editor-last2=DeLong|editor-first2=Edward F.|editor-last3=Lory|editor-first3=Stephen|editor-last4=Stackebrandt|editor-first4=Erko|editor-last5=Thompson|editor-first5=Fabiano}}</ref>

== Taxonomy ==
The genus ''Bordetella'' contains nine species: ''B. pertussis'', ''B. parapertussis'', ''B. bronchiseptica'', ''B. avium'', ''B. hinzii'', ''B. holmesii'', ''B. trematum, B. ansorpii'' and ''B.petrii.'' The first three listed form a closely related phylogenetical group.<ref name=":1" />

''B. parapertussis'' causes a disease similar to whooping cough in humans. ''B. bronchiseptica'' infects a range of mammal hosts, including humans, and causes a spectrum of respiratory disorders.<ref name=":1" />


==Pertussis==
==Pertussis==
Line 24: Line 32:


Pertussis is an infection of the [[respiratory system]] characterized by a “whooping” sound when the person breathes in. In the US, it killed between 10,000 and 20,000 people per year before a vaccine was available.{{citation needed|date=December 2015}} [[Vaccination]] has transformed this; between 1985 and 1988, fewer than 100 children died from pertussis. Worldwide in 2000, according to the WHO, around 39 million people were infected annually and about 297,000 died. A graph is available showing the dramatic effect of introducing vaccination in England.<ref>{{cite web |url=http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/WhoopingCough/EpidemiologicalData/whoo45VacCover1940to2008/+ |title=Whooping Cough (Pertussis) |publisher=HPA |accessdate=2009-04-12}}</ref>
Pertussis is an infection of the [[respiratory system]] characterized by a “whooping” sound when the person breathes in. In the US, it killed between 10,000 and 20,000 people per year before a vaccine was available.{{citation needed|date=December 2015}} [[Vaccination]] has transformed this; between 1985 and 1988, fewer than 100 children died from pertussis. Worldwide in 2000, according to the WHO, around 39 million people were infected annually and about 297,000 died. A graph is available showing the dramatic effect of introducing vaccination in England.<ref>{{cite web |url=http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/WhoopingCough/EpidemiologicalData/whoo45VacCover1940to2008/+ |title=Whooping Cough (Pertussis) |publisher=HPA |accessdate=2009-04-12}}</ref>
⚫
''B. pertussis'' infects its host by colonizing lung epithelial cells. The bacterium contains a surface protein, [[filamentous haemagglutinin adhesin]], which binds to the [[sulfatide]]s found on cilia of epithelial cells. Once anchored, the bacterium produces [[tracheal cytotoxin]], which stops the cilia from beating. This prevents the cilia from clearing debris from the lungs, so the body responds by sending the host into a coughing fit. These coughs expel some bacteria into the air, which are free to infect other hosts.


⚫
''B. pertussis'' infects its host by colonizing lung epithelial cells. The bacterium contains a surface protein, [[filamentous haemagglutinin adhesin]], which binds to the [[sulfatide]]s found on cilia of epithelial cells. Other adhesins are fimbriae and petractin.<ref name=":1" /> Once anchored, the bacterium produces [[tracheal cytotoxin]], which stops the cilia from beating. This prevents the cilia from clearing debris from the lungs, so the body responds by sending the host into a coughing fit. These coughs expel some bacteria into the air, which are free to infect other hosts.
⚫
''B. pertussis'' has the ability to inhibit the function of the host's immune system. The toxin, known as [[pertussis toxin]] (or PTx), inhibits [[G protein]] coupling that regulates an [[adenylate cyclase]]-mediated conversion of [[Adenosine triphosphate|ATP]] to [[cyclic AMP]]. The end result is phagocytes convert too much ATP to cyclic AMP, which can cause disturbances in cellular signaling mechanisms, and prevent phagocytes from correctly responding to an infection. PTx, formerly known as lymphocytosis-promoting factor, causes a decrease in the entry of lymphocytes into lymph nodes, which can lead to a condition known as [[lymphocytosis]], with a complete [[lymphocyte]] count of over 4000/μl in adults or over 8000/μl in children. This is unique in that many bacterial infections illustrate neutrophil-predominance instead.


⚫
''B. pertussis'' has the ability to inhibit the function of the host's immune system. The toxin, known as [[pertussis toxin]] (or PTx), inhibits [[G protein]] coupling that regulates an [[adenylate cyclase]]-mediated conversion of [[Adenosine triphosphate|ATP]] to [[cyclic AMP]]. The end result is phagocytes convert too much ATP to cyclic AMP, which can cause disturbances in cellular signaling mechanisms, and prevent phagocytes from correctly responding to an infection. PTx, formerly known as lymphocytosis-promoting factor, causes a decrease in the entry of lymphocytes into lymph nodes, which can lead to a condition known as [[lymphocytosis]], with a complete [[lymphocyte]] count of over 4000/μl in adults or over 8000/μl in children. Beside targeting lymphocytes, it limits neutrophil migration to the lungs. It also decreases the function of tissue-resident macrophages, that are responsible for some bacterial clearance.<ref name=":2">{{Cite journal|last=Carbonetti|first=Nicholas H|date=2007-06-01|title=Immunomodulation in the pathogenesis of Bordetella pertussis infection and disease|url=http://www.sciencedirect.com/science/article/pii/S1471489207000598|journal=Current Opinion in Pharmacology|series=Respiratory/Musculoskeletal|volume=7|issue=3|pages=272–278|doi=10.1016/j.coph.2006.12.004|issn=1471-4892}}</ref>
⚫
The infection occurs mostly in children under the age of one when they are [[Immunization|unimmunized]], or children with faded [[Immunity (medical)|immunity]], normally around the ages 11 through 18. The signs and symptoms are similar to a [[common cold]]: runny nose, [[sneezing]], mild [[cough]], and low-grade [[fever]]. The patient becomes most contagious during the [[catarrhal]] stage of infection, normally two weeks after the coughing begins. It may become airborne when the person coughs, sneezes, or laughs. [[DPT vaccine|Pertussis vaccine]] is part of the [[diphtheria]], [[tetanus]], and acellular pertussis (DTaP) immunization. The [[paroxysmal]] cough precedes a crowing inspiratory sound characteristic of pertussis. After a spell, the patient might make a “whooping” sound when breathing in, or may vomit. Adults have milder symptoms, such as prolonged coughing without the “whoop”. Infants less than six months also may not have the typical whoop. A coughing spell may last a minute or more, producing [[cyanosis]], [[apnoea]], and [[seizures]]. However, when not in a coughing fit, the patient does not experience trouble breathing. This is because ''B. pertussis'' inhibits the immune response, so very little mucus is generated in the lungs.

Another toxin important for inhibiting the immune response is the adenylate cyclate toxin. This toxin has an intrinsic adenylate cyclase activity, increasing intracellular cAMP almost immediately. Also, it is capable of forming pores in the membrane of the target cell. These pores are cation-specific. <ref name=":1" /><ref>{{Cite journal|last=Sebo|first=Peter|last2=Osicka|first2=Radim|last3=Masin|first3=Jiri|date=2014-08-04|title=Adenylate cyclase toxin-hemolysin relevance for pertussis vaccines|url=http://dx.doi.org/10.1586/14760584.2014.944900|journal=Expert Review of Vaccines|volume=13|issue=10|pages=1215–1227|doi=10.1586/14760584.2014.944900|issn=1476-0584}}</ref> The resulting deregulation of cell signaling leads to blocking of phagocytosis and killing of bacteria by neutrophils. Also it inhibits maturation of dendritic cells and their migration to the lymph nodes.<ref name=":2" />

⚫
The infection occurs mostly in children under the age of one when they are [[Immunization|unimmunized]], or children with faded [[Immunity (medical)|immunity]], normally around the ages 11 through 18. The signs and symptoms are similar to a [[common cold]]: runny nose, [[sneezing]], mild [[cough]], and low-grade [[fever]]. The patient becomes most contagious during the [[catarrhal]] stage of infection, normally two weeks after the coughing begins. It may become airborne when the person coughs, sneezes, or laughs. The [[paroxysmal]] cough precedes a crowing inspiratory sound characteristic of pertussis. After a spell, the patient might make a “whooping” sound when breathing in, or may vomit. Adults have milder symptoms, such as prolonged coughing without the “whoop”. Infants less than six months also may not have the typical whoop. A coughing spell may last a minute or more, producing [[cyanosis]], [[apnoea]], and [[seizures]]. However, when not in a coughing fit, the patient does not experience trouble breathing. This is because ''B. pertussis'' inhibits the immune response, so very little mucus is generated in the lungs.


A prolonged cough may be irritating and sometimes a disabling cough may go undiagnosed in adults for many months.
A prolonged cough may be irritating and sometimes a disabling cough may go undiagnosed in adults for many months.

== Prevention ==
[[DPT vaccine|Pertussis vaccine]] is widely used since the half of the 20. century. <ref>{{Cite journal|last=Sealey|first=Katie L.|last2=Belcher|first2=Thomas|last3=Preston|first3=Andrew|date=2016-06-01|title=Bordetella pertussis epidemiology and evolution in the light of pertussis resurgence|url=http://www.sciencedirect.com/science/article/pii/S1567134816300636|journal=Infection, Genetics and Evolution|volume=40|pages=136–143|doi=10.1016/j.meegid.2016.02.032|issn=1567-1348}}</ref><ref name=":0" /> The first vaccines were whole-cell vaccines, composed of chemically inactivated bacteria. They are being replaced by acellular vaccines, composed of purified surface antigens, mainly fimbriae, filamentous haemaglutinin, pertactin and pertussis toxin. It is part of the [[diphtheria]], [[tetanus]], and acellular pertussis (DTaP) immunization.<ref name=":0" />


==As a zoonotic disease==
==As a zoonotic disease==
Line 43: Line 57:


The organism is [[oxidase test|oxidase]] positive, but [[Rapid urease test|urease]], [[nitrate reductase]], and [[citrate]] negative. It is also not motile.
The organism is [[oxidase test|oxidase]] positive, but [[Rapid urease test|urease]], [[nitrate reductase]], and [[citrate]] negative. It is also not motile.

== Treatment ==
Whooping cough is treated by [[Macrolide|macrolides]], for example [[erythromycin]]. The therapy is most effective when started during the incubation period or the catarrhal period. When applied during the paroxysmal cough phase, the time of reconvalescence is not affected, only further transmission is prevented.<ref name=":0" />


==References==
==References==

Revision as of 21:36, 10 February 2019

Bordetella pertussis
Scientific classification Edit this classification
Domain: Bacteria
Phylum: Pseudomonadota
Class: Betaproteobacteria
Order: Burkholderiales
Family: Alcaligenaceae
Genus: Bordetella
Species:
B. pertussis
Binomial name
Bordetella pertussis
(Bergey et al. 1923) Moreno-López 1952

Bordetella pertussis is a Gram-negative, aerobic, pathogenic, encapsulated coccobacillus of the genus Bordetella, and the causative agent of pertussis or whooping cough. Unlike B. bronchiseptica, B. pertussis is not motile. Its virulence factors include pertussis toxin, filamentous hæmagglutinin, pertactin, fimbria, and tracheal cytotoxin.

The bacterium is spread by airborne droplets; its incubation period is 7–10 days on average (range 6–20 days).[1][2] Humans are the only known reservoir for B. pertussis.[3] The complete B. pertussis genome of 4,086,186 base pairs was published in 2003.[4] Compared to its closest relative B. bronchiseptica, the genome size is greatly reduced. This is mainly due to the adaptation to one host species (human) and the loss of capability of survival outside of a host body.[5]

History

The first to describe this disease was french physician Guillaume de Baillou after the epidemic of 1578. The causative agent of pertussis was identified and isolated by Jules Bordet and Octave Gengou.[6]

Taxonomy

The genus Bordetella contains nine species: B. pertussis, B. parapertussis, B. bronchiseptica, B. avium, B. hinzii, B. holmesii, B. trematum, B. ansorpii and B.petrii. The first three listed form a closely related phylogenetical group.[5]

B. parapertussis causes a disease similar to whooping cough in humans. B. bronchiseptica infects a range of mammal hosts, including humans, and causes a spectrum of respiratory disorders.[5]

Pertussis

Main article: Pertussis

Pertussis is an infection of the respiratory system characterized by a “whooping” sound when the person breathes in. In the US, it killed between 10,000 and 20,000 people per year before a vaccine was available.[citation needed] Vaccination has transformed this; between 1985 and 1988, fewer than 100 children died from pertussis. Worldwide in 2000, according to the WHO, around 39 million people were infected annually and about 297,000 died. A graph is available showing the dramatic effect of introducing vaccination in England.[7]

B. pertussis infects its host by colonizing lung epithelial cells. The bacterium contains a surface protein, filamentous haemagglutinin adhesin, which binds to the sulfatides found on cilia of epithelial cells. Other adhesins are fimbriae and petractin.[5] Once anchored, the bacterium produces tracheal cytotoxin, which stops the cilia from beating. This prevents the cilia from clearing debris from the lungs, so the body responds by sending the host into a coughing fit. These coughs expel some bacteria into the air, which are free to infect other hosts.

B. pertussis has the ability to inhibit the function of the host's immune system. The toxin, known as pertussis toxin (or PTx), inhibits G protein coupling that regulates an adenylate cyclase-mediated conversion of ATP to cyclic AMP. The end result is phagocytes convert too much ATP to cyclic AMP, which can cause disturbances in cellular signaling mechanisms, and prevent phagocytes from correctly responding to an infection. PTx, formerly known as lymphocytosis-promoting factor, causes a decrease in the entry of lymphocytes into lymph nodes, which can lead to a condition known as lymphocytosis, with a complete lymphocyte count of over 4000/μl in adults or over 8000/μl in children. Beside targeting lymphocytes, it limits neutrophil migration to the lungs. It also decreases the function of tissue-resident macrophages, that are responsible for some bacterial clearance.[8]

Another toxin important for inhibiting the immune response is the adenylate cyclate toxin. This toxin has an intrinsic adenylate cyclase activity, increasing intracellular cAMP almost immediately. Also, it is capable of forming pores in the membrane of the target cell. These pores are cation-specific. [5][9] The resulting deregulation of cell signaling leads to blocking of phagocytosis and killing of bacteria by neutrophils. Also it inhibits maturation of dendritic cells and their migration to the lymph nodes.[8]

The infection occurs mostly in children under the age of one when they are unimmunized, or children with faded immunity, normally around the ages 11 through 18. The signs and symptoms are similar to a common cold: runny nose, sneezing, mild cough, and low-grade fever. The patient becomes most contagious during the catarrhal stage of infection, normally two weeks after the coughing begins. It may become airborne when the person coughs, sneezes, or laughs. The paroxysmal cough precedes a crowing inspiratory sound characteristic of pertussis. After a spell, the patient might make a “whooping” sound when breathing in, or may vomit. Adults have milder symptoms, such as prolonged coughing without the “whoop”. Infants less than six months also may not have the typical whoop. A coughing spell may last a minute or more, producing cyanosis, apnoea, and seizures. However, when not in a coughing fit, the patient does not experience trouble breathing. This is because B. pertussis inhibits the immune response, so very little mucus is generated in the lungs.

A prolonged cough may be irritating and sometimes a disabling cough may go undiagnosed in adults for many months.

Prevention

Pertussis vaccine is widely used since the half of the 20. century. [10][2] The first vaccines were whole-cell vaccines, composed of chemically inactivated bacteria. They are being replaced by acellular vaccines, composed of purified surface antigens, mainly fimbriae, filamentous haemaglutinin, pertactin and pertussis toxin. It is part of the diphtheria, tetanus, and acellular pertussis (DTaP) immunization.[2]

As a zoonotic disease

Uncertainties of B. pertussis and whooping cough as a zoonotic disease have existed since around 1910,[11][12] but in the 1930s, the bacteria were found to have lost their virulent power when repeatedly spread on agar media. This explained the difficulties in reproducing results from different studies, as the preinoculating handling of the bacteria were not standardized among scientists.[13]

At least some primate species are highly sensitive to B. pertussis, and develop a clinical whooping cough in high incidence when exposed to low inoculation doses.[14][15] Whether the bacteria spread naturally in wild animal populations has not been confirmed satisfactorily by laboratory diagnosis, but whooping cough has been found among wild gorillas.[16] Several zoos have learned to vaccinate their primates against whooping cough.[17]

Diagnosis

A nasopharyngeal or an oropharynx swab is sent to the bacteriology laboratory for Gram stain (Gram-negative, coccobacilli, diplococci arrangement), growth on Bordet-Gengou agar or BCYE plate with added cephalosporin to select for the organism, which shows mercury drop-like colonies. B. pertussis can also be detected by PCR, which is more sensitive than culture. The primers used for PCR usually target the transposable elements IS481 and IS1001.[18]

Several diagnostic tests are available, especially ELISA kits. These are designed to detect FHA and/or PT antibodies of IgG, IgA, or IgM. Some kits use a combination of antigens which lead to a higher sensitivity, but might also make the interpretation of the results harder, since one cannot know which antibody has been detected.

The organism is oxidase positive, but urease, nitrate reductase, and citrate negative. It is also not motile.

Treatment

Whooping cough is treated by macrolides, for example erythromycin. The therapy is most effective when started during the incubation period or the catarrhal period. When applied during the paroxysmal cough phase, the time of reconvalescence is not affected, only further transmission is prevented.[2]

References

  1. ^ Heymann, David L. (ed): Pertussis; in Control of Communicable Diseases Manual. p. 457. American Public Health Association, Washington DC, 2008, ISBN 978-0-87553-189-2
  2. ^ a b c d Organization., Organisation mondiale de la santé. World Health (1998-). Relevé épidémiologique hebdomadaire (Online) = Weekly epidemiological record. Organisation mondiale de la sante. OCLC 301147153. {{cite book}}: Check date values in: |date= (help)
  3. ^ Pink Book 2015, Ch. 16: Pertussis
  4. ^ Parkhill J, et al. (2003). "Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica". Nature Genetics. 35 (1): 32–40. doi:10.1038/ng1227. PMID 12910271.
  5. ^ a b c d e Bordetella : molecular microbiology. Locht, Camille. Wymondham: Horizon Bioscience. 2007. ISBN 9781904933311. OCLC 159579443.{{cite book}}: CS1 maint: others (link)
  6. ^ Rosenberg, Eugene; DeLong, Edward F.; Lory, Stephen; Stackebrandt, Erko; Thompson, Fabiano, eds. (2013). The Prokaryotes. Berlin, Heidelberg: Springer Berlin Heidelberg. doi:10.1007/978-3-642-30144-5. ISBN 9783642301438.
  7. ^ "Whooping Cough (Pertussis)". HPA. Retrieved 2009-04-12.
  8. ^ a b Carbonetti, Nicholas H (2007-06-01). "Immunomodulation in the pathogenesis of Bordetella pertussis infection and disease". Current Opinion in Pharmacology. Respiratory/Musculoskeletal. 7 (3): 272–278. doi:10.1016/j.coph.2006.12.004. ISSN 1471-4892.
  9. ^ Sebo, Peter; Osicka, Radim; Masin, Jiri (2014-08-04). "Adenylate cyclase toxin-hemolysin relevance for pertussis vaccines". Expert Review of Vaccines. 13 (10): 1215–1227. doi:10.1586/14760584.2014.944900. ISSN 1476-0584.
  10. ^ Sealey, Katie L.; Belcher, Thomas; Preston, Andrew (2016-06-01). "Bordetella pertussis epidemiology and evolution in the light of pertussis resurgence". Infection, Genetics and Evolution. 40: 136–143. doi:10.1016/j.meegid.2016.02.032. ISSN 1567-1348.
  11. ^ Inaba, I. (1912). "Über den Bordet-Gengouschen Keuchhustenbacillus Übertragungsversuches des Keuchenhustens auf Tiere". Zeitschrift für Kinderheilkunde. 4 (1): 252–264. doi:10.1007/BF02088879.
  12. ^ Bachamn, W.; Burghard, E. (1925). "Der Nachweis der Bordet–Gengouschen Bacillen und ihre ätiologische Bedeutung für den Keuchenhusten". Zeitschrift für Kinderheilkunde. 39 (5): 465–483. doi:10.1007/BF02225286.
  13. ^ Shibley GS, Hoelscher H (1934). "Studies on whooping cough. I. Type-specific (S) and dissociation (R) forms of Hemophilus pertussis". Journal of Experimental Medicine. 60 (4): 403–18. doi:10.1084/jem.60.4.403. PMC 2132401. PMID 19870311.
  14. ^ Gustavsson OE, Röken BO, Serrander R (1990). "An epizootic of whooping cough among chimpanzees in a zoo". Folia Primatologica. 55 (1): 45–50. doi:10.1159/000156498. PMID 2394416.
  15. ^ Warfel JM, Merkel TJ (2014). "The baboon model of pertussis: effective use and lessons for pertussis vaccines". Expert Review of Vaccines. 13 (10): 1241–52. doi:10.1586/14760584.2014.946016. PMID 25182980.
  16. ^ Kingdon, Jonathan; Happold, David; Butynski, Thomas (2013). Primates. Mammals of Africa. Vol. 2. A&C Black. p. 51. ISBN 978-1-4081-8996-2.
  17. ^ Loomis, M.R. (1985). "Immunoprofylaxis in infant great apes". In Graham, C.E.; Bowen, J.A. (eds.). Clinical management of infant great apes: proceedings of a workshop on clinical management of infant great apes, held during the IXth Congress of the International Primatological Society. Monographs in Primatology. Vol. 5. Liss. pp. 107–112. ISBN 978-0845134047.
  18. ^ Nieves DJ, Heininger U (2016). Bordetella pertussis. Vol. 4. pp. 311–339. doi:10.1128/microbiolspec.EI10-0008-2015. ISBN 9781555819446. PMID 27337481. {{cite book}}: |journal= ignored (help)

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Bordetella_pertussis&oldid=882711098"